We assessed the utility of using a p63/a-methylacyl-coenzyme-A racemase (AMACR) antibody cocktail on destained H&E-stained sections. We transferred 61 stored (7-11 months old) and 10 recent (<1 month old) H&E-stained sections of prostate needle biopsy tissues to charged slides and subsequently stained them with a p63/AMACR immunohistochemical antibody cocktail. The AMACR and p63 staining intens...

The present study examines the expression of p63, glutathione S-transferase-pi (GSTP1) and alpha-methylacyl-CoAracemase (AMACR) in serial slices in proliferative inflammatory atrophy (PIA) in order to implicate that some of the basal cells are probably the putative human prostate carcinoma stem cells (PHPCSC). Archived tissue sections obtained after radical prostatectomy from cases (n=30) compr...

BACKGROUND To assess if the variants of (R)-alpha-methyl-CoA racemase (AMACR) gene would be associated with the risk of sporadic prostate cancer in ethnically homogenous Koreans. MATERIALS AND METHODS We enrolled 194 patients with prostate cancer and 169 healthy controls. A total of 17 single nucleotide polymorphisms of the AMACR gene were selected. The distribution of each genotype and haplo...

BACKGROUND. Expression of the a-methylacyl-CoA racemase (AMACR) gene has been established as a sensitive and specific biomarker for the diagnosis of prostate cancer. An initial study has also suggested that the risk of familial (but not sporadic) prostate cancer may be associated with germline variation in the AMACR gene. METHODS. In a study of brothers discordant for the diagnosis of prostate ...

41 Background: A promising prostate cancer biomarker, alpha-methylacyl-CoA racemase (AMACR), has demonstrated the ability to distinguish cancer from healthy and benign cells with high sensitivity and specificity. However the lack of a good clinical assay has limited its translation into the clinic. Here we report on the development of a single use disposable biosensor for AMACR detection. MET...

BACKGROUND AND OBJECTIVE Prostate cancer is the second leading cause of death in men. The localized disease often responds to conventional therapies like androgen ablation via castration and/or administration of chemical inhibitors but advanced disease resistant to any curative therapies is still challenge for investigators. There are increasing efforts to enhance the possibility of finding pos...

We assessed the usefulness of immunohistochemical analysis with a 3-antibody cocktail (alpha-methylacyl coenzyme A racemase [AMACR, or P504S], 34betaE12, p63) and a double-chromogen reaction for detection of limited prostate cancer in 138 needle biopsy specimens, including 82 with small foci of prostatic adenocarcinoma and 56 benign prostates. When carcinoma was present, red cytoplasmic granula...

Partial atrophy is the most common benign mimicker of prostate cancer on needle biopsy. Of 3916 prostate needle core biopsy cases received in our consultation service over a period of 3 months (March 1, 2007 to May 31, 2007), 170 cases (4.3%) with partial atrophy were diagnosed as atypical glands by outside pathologists and prospectively identified. We supplemented our material with 108 cases o...

Sir, Alpha-methylacyl-CoA racemase (AMACR) is an enzyme localised in peroxisomes and mitochondria, and involved in metabolism of branched chain fatty acids as well as some drugs. It is also a well recognised immunohistochemical (IHC) marker, particularly helpful in the diagnosis of limited prostatic adenocarcinoma. However, its usefulness in oncology and anatomical pathology practice may be muc...

Purpose: With the recent discovery that -methlyacly-coenzyme A racemase (AMACR) is over expressed in a majority of prostate cancer (CaP) specimens we developed a novel polymerase chain reaction (PCR) based approach that would predict the presence of CaP from prostatic secretions. Materials and Methods: A total of 21 patients were enlisted in this study, including 10 with CaP, 2 with high grade ...